Fosamax Osteonecrosis of the Jaw Attorney: Statute of Limitations for Fosamax in New Jersey

Latest update (2026-05)

FDA enforcement record (Ongoing): This recall is being conducted due to out of specification assay results in a limited number of bottles that were stored on side. [source]

From General Health Education to Specific Legal Concerns

For decades, general health and science information has served as the foundation for public understanding of medical conditions and treatment options. This broad educational context has empowered individuals to engage with healthcare providers about preventive measures and therapeutic interventions. Within this framework, the safe use of prescription medications has always been a central concern, emphasizing the importance of informed decision-making and awareness of potential side effects. As this legacy of health literacy evolves, attention naturally shifts to specific clinical scenarios where medication use intersects with serious adverse outcomes. One such area involves bisphosphonate therapies, commonly prescribed for bone density management. In particular, long-term exposure to medications like Fosamax has been associated with a rare but severe condition: osteonecrosis of the jaw. This complication, though infrequent, raises critical questions about patient monitoring and legal accountability. The transition from general health education to occupational exposure concern becomes evident when considering the role of legal professionals. Attorneys specializing in pharmaceutical litigation now address cases where individuals have developed osteonecrosis of the jaw following Fosamax use. In New Jersey, the statute of limitations imposes strict timeframes for filing such claims, making timely legal consultation essential. This pivot from broad health awareness to specific legal and occupational risk underscores the need for specialized guidance in navigating complex medical-legal landscapes.

Understanding Fosamax and Its Mechanism

Fosamax (alendronate) is a bisphosphonate medication approved for the treatment and prevention of osteoporosis in postmenopausal women, treatment to increase bone mass in men with osteoporosis, treatment of glucocorticoid-induced osteoporosis, and treatment of Paget's disease of bone (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). The drug works by inhibiting bone resorption, which increases bone mass and reduces fracture risk, including hip and spine fractures (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). However, a rare but serious adverse effect associated with bisphosphonates, including Fosamax, is osteonecrosis of the jaw (ONJ). Osteonecrosis of the jaw is a condition characterized by exposed, non-healing bone in the maxillofacial region, which can occur spontaneously but is generally associated with tooth extraction and/or local infection with delayed healing (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). The clinical presentation of ONJ often involves pain, swelling, infection, and exposed bone in the jaw, which can lead to significant morbidity. Diagnosis is typically based on clinical examination and imaging, with a history of bisphosphonate use being a key risk factor.

Mechanistic Pathways and Risk Factors for ONJ

The mechanistic pathways linking Fosamax to ONJ are not fully understood but are believed to involve the drug's potent inhibition of osteoclast activity. Bisphosphonates like alendronate accumulate in bone and suppress bone turnover, which may impair the ability of the jawbone to repair microdamage and respond to local stressors such as dental procedures or infection. This suppression of bone remodeling, combined with the anti-angiogenic properties of bisphosphonates, may contribute to the development of ONJ. Known risk factors for ONJ include invasive dental procedures (e.g., tooth extraction, dental implants, boney surgery), diagnosis of cancer, concomitant therapies (e.g., chemotherapy, corticosteroids, angiogenesis inhibitors), poor oral hygiene, and co-morbid disorders such as periodontal disease, anemia, coagulopathy, infection, and ill-fitting dentures (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). The risk of ONJ may increase with longer duration of bisphosphonate exposure (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). The time to onset of ONJ symptoms after starting Fosamax can vary from one day to several months (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). In clinical studies, most patients who developed symptoms had relief after stopping the drug, but a subset experienced recurrence when rechallenged with the same or another bisphosphonate (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). The incidence of ONJ is rare; one study found that the incidence of atypical femoral fracture or ONJ was uncommon and rare, respectively (https://pubmed.ncbi.nlm.nih.gov/42046648/).

Legal Considerations and Statute of Limitations in New Jersey

Despite its rarity, the severity of ONJ underscores the importance of adequate warnings and patient monitoring. Regarding the adequacy of warnings, the Fosamax label includes a section on osteonecrosis of the jaw under "Warnings and Precautions" (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). The label notes that ONJ has been reported in patients taking bisphosphonates, including Fosamax, and lists known risk factors. It also advises that for patients requiring invasive dental procedures, discontinuation of bisphosphonate treatment may reduce the risk for ONJ (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). However, the optimal duration of Fosamax use has not been determined, and for patients at low risk for fracture, drug discontinuation after 3 to 5 years of use may be considered (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). This suggests that long-term use may increase ONJ risk, but the label does not provide specific guidance on monitoring for ONJ beyond general warnings. For patients affected by ONJ after taking Fosamax, attorney-related considerations are important. In New Jersey, the statute of limitations for product liability claims, including those involving pharmaceutical injuries, is generally two years from the date the injury was discovered or should have been discovered. This timeline is critical for patients who develop ONJ, as the condition may not be immediately recognized as related to Fosamax use. The timeline between exposure and documented harm can vary widely, with symptoms appearing from one day to several months after starting the drug (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). Patients who experience ONJ after long-term use may face challenges in establishing the causal link, especially if other risk factors are present. Consulting an attorney experienced in pharmaceutical litigation can help patients understand their legal rights and the applicable deadlines for filing a claim.

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Frequently Asked Questions

What is the statute of limitations for Fosamax-related ONJ claims in New Jersey?

In New Jersey, the statute of limitations for product liability claims, including those involving pharmaceutical injuries like osteonecrosis of the jaw (ONJ) from Fosamax, is generally two years from the date the injury was discovered or should have been discovered. It is crucial to consult an attorney promptly to ensure your claim is filed within this timeframe.

What are the known risk factors for developing ONJ from Fosamax?

Known risk factors for ONJ include invasive dental procedures (e.g., tooth extraction, dental implants), cancer diagnosis, concomitant therapies (chemotherapy, corticosteroids, angiogenesis inhibitors), poor oral hygiene, and co-morbid disorders such as periodontal disease, anemia, coagulopathy, infection, and ill-fitting dentures. Longer duration of bisphosphonate exposure may increase risk (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1).

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Fosamax exposure and a confirmed Osteonecrosis of the Jaw diagnosis may request an independent eligibility review. [Begin Assessment]

References

Request a Free Case Review

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.